Tongjitang Chinese Medicines Company to Announce Second Quarter 2010 Financial Results on August 18, 2010

SHENZHEN, China, Aug. 11 /PRNewswire-Asia-FirstCall/ -- Tongjitang Chinese Medicines Company (the "Company"; NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that it plans to release its second quarter 2010 financial results after market close on Wednesday, August 18, 2010.

Tongjitang's management team will hold a conference call on Thursday, August 19, at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing/Hong Kong time) following the announcement. Listeners may access the call by dialing the following numbers:

     United States toll free:      1-888-259-8389
     Hong Kong toll free:          800-903-658
     Northern China toll free:     10-800-714-1504
     Southern China toll free:     10-800-140-1379
     International:                1-913-312-1483

Listeners may access the replay from approximately two hours after the call ends through August 26, 2010 by dialing the following numbers:

     United States toll free:      1-888-203-1112
     International:                1-719-457-0820
     Password:                     6642433

An audio webcast of the call will also be available through the Company's website at http://www.tongjitang.com .

About Tongjitang Chinese Medicines Company

Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante and Anhui Jingfang, is a vertically integrated specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China. Tongjitang's principal executive offices are located in Shenzhen, China.

Tongjitang's flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi. In addition to Xianling Gubao, the Company manufactures and markets 36 other modernized traditional Chinese medicine products and 36 western medicines. Please visit http://www.tongjitang.com for more information.

    For more information, please contact:

    ICR, LLC
     Ashley M. Ammon or Christine Duan
     Tel:   +1-203-682-8200 (Investor Relations)

SOURCE Tongjitang Chinese Medicines Company